

Historically, most women diagnosed with breast cancers would require both hormonal therapy and chemotherapy to lower the risk of cancer returning after breast surgery.

A new test is now available to help you and your doctor decide whether you may be sufficiently treated with hormone therapy alone.¹

Getting tested is easy

- Speak with your physician to understand whether Prosigna is a suitable test for you.
- The test does not require additional surgery or procedures.
- The test can be performed on cancer tissue specimen preserved from your original surgery.
- You would expect the test results to be ready within 10 working days, upon receipt of your cancer tissue specimen in our laboratory.

Proceed with **confidence.**



REFERENCES:

1. Gnant M. Ann Oncol 2013 doi: 10.1093/annonc/mdt494
2. Nielson TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16(21):5222-5232.
3. Parker JS, Mullins M, Cheang, Mc, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160-1167

© 2014 NanoString Technologies. All rights reserved.
NanoString Technologies logo, Prosigna and the Prosigna logo are registered trademarks and/or trademarks of NanoString Technologies, Inc. in various jurisdictions.



37 Jalan Pemimpin
#08-05 Mapex
Singapore 577177
t: +65 6251 0136 f: +65 6251 0132
www.clearbridgemedical.com

E&OE
Mar 2018



Making the right choice about breast cancer treatment

In partnership with



What is Prosigna® ?

- Prosigna® is a test which looks at activity of 50 genes in your cancer cells, to predict the chances of **your cancer returning over the next 10 years.**
- Prosigna® **informs decision about cancer treatment after surgery.**
- Accuracy of Prosigna® to predict cancer recurrence has been proven in independent clinical studies, involving thousands of women.
- Prosigna® is endorsed by independent regulatory organisations and professional oncology organisations worldwide.

Who should take Prosigna® breast cancer gene signature test?

Post-menopausal women with newly diagnosed, early stage invasive breast cancer treated with endocrine therapy

Hormone receptor positive (ER or PR)

Lymph node-negative or Lymph node-positive

What information does Prosigna® provide?

The Prosigna® report provides three important sets of information:

- **Your Intrinsic Subtype:**
 - This assigns your cancer to one of four molecular classes: Luminal A, Luminal B, HER2 enriched or Basal-like. Subtypes provide additional information to your doctor regarding the underlying biology, characteristics and likely responses of your cancer to treatment.^{2,3}
- **Your Prosigna® Score:**
 - This is a numerical value on a 0-to-100 scale. A lower number indicates your cancer is less likely to return. A higher number indicates there is a higher chance your cancer may return.
- **Your risk of cancer recurrence (Low, Intermediate, High):**
 - The risk of recurrence is provided as a percentage. This result indicates how likely your cancer will return within 10 years, when treated with hormonal therapy alone.

Understanding stages of breast cancer evaluation

